MoldCo announced the public launch of the company to address the endemic public health crisis of chronic health issues caused by mold. And the company has raised $3 million in pre-seed funding with participation from Starship Ventures, SALT, Conscience VC, Boost VC, Night Ventures, Bleu Capital, Behind Genius Ventures, and Moth Fund.
MoldCo was launched by CEO Ariana Thacker, a former venture capital investor and Founding Partner of Conscience VC, based on her experiences with severe symptoms due to mold exposure. And after determining that her health challenges were caused by toxic mold, she dived deep into the research while connecting with top experts in the field. Based on this knowledge, she built MoldCo to provide evidence-based, real solutions for people facing similar challenges.
MoldCo is now accepting patients in select states and will use the funding to expand nationwide in 2025.
MoldCo’s approach is guided by a patented, published, and evidence-based approach used to treat over 30,000 patients with Mold Illness, known as Chronic Inflammatory Response Syndrome (CIRS). And MoldCo’s customers receive access to mold-certified clinician care, specialized lab tests, and evidence-based treatments.
Studies have shown that over 50% of U.S. households have mold, dampness, and water damage, and the EPA claims 85% of office buildings have experienced water damage. However, mainstream medicine has not traditionally recognized or addressed the pervasive and debilitating dangers of mold to people’s health or its links to medical conditions.
There is now increasing recognition of the many health issues caused by mold. And there is also growing evidence of mold problems in large-scale locations such as in military housing. MoldCo is poised to address this long-ignored area.
KEY QUOTES:
“I learned first-hand the serious and neglected public health crisis caused by mold. Now with MoldCo, people have a company on their side with an evidence-based understanding of the health impacts of mold to provide treatments and care accessibly and affordably.”
- Ariana Thacker
“Mold can cause debilitating, chronic conditions and has not been adequately addressed by traditional medical institutions. MoldCo is the first company to provide a research-backed solution to address it. Now with MoldCo, individuals facing this serious issue will no longer be alone.”
- Sean Hoge, Founder and General Partner at Starship Ventures
“The days of simply living with mold and biotoxin-related illness have been replaced by peer-reviewed treatment protocols, developed from nearly three decades of research and evidence-based care.”
- Ritchie Shoemaker, M.D., a recognized world leader and pioneer in the treatment of mold and biotoxin-related illness, and MoldCo’s Founding Physician
